Antispasmodic drugs such as dicyclomine (Bentyl) and hyoscyamine (Levsin) relieve the stomach cramps brought on by IBS by relaxing the smooth muscle of the gut. They also may cause constipation, so they aren't usually prescribed for people who suffer from IBS-C. Other side effects are dry mouth, drowsiness, and blurred vision.

The global Anti-spasmodic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Anti-spasmodic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-spasmodic Drugs.

Report Scope

The Anti-spasmodic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-spasmodic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Anti-spasmodic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Anti-spasmodic Drugs Market Report

Report Metric	Details
Report Name	Anti-spasmodic Drugs Market
CAGR	5%
Segment by Type	Antimuscarinics Smooth Muscle Relaxants
Segment by Application	Offline Channel Online Channel
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Allergan, Ipsen, Teva Pharmaceuticals, Novartis, Johnson & Johnson, Takeda Pharmaceutical, Sun Pharmaceutical Industries, Merz Pharma, Mylan, Fresenius Kabi, Endo International, Daewoong Pharmaceutical, Acorda Therapeutics, SteriMax, Emcure Pharmaceuticals, Sawai Pharmaceutical, Orient Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-spasmodic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Anti-spasmodic Drugs Market report?

Ans: The main players in the Anti-spasmodic Drugs Market are Pfizer, Allergan, Ipsen, Teva Pharmaceuticals, Novartis, Johnson & Johnson, Takeda Pharmaceutical, Sun Pharmaceutical Industries, Merz Pharma, Mylan, Fresenius Kabi, Endo International, Daewoong Pharmaceutical, Acorda Therapeutics, SteriMax, Emcure Pharmaceuticals, Sawai Pharmaceutical, Orient Pharma

What are the Application segmentation covered in the Anti-spasmodic Drugs Market report?

Ans: The Applications covered in the Anti-spasmodic Drugs Market report are Offline Channel, Online Channel

What are the Type segmentation covered in the Anti-spasmodic Drugs Market report?

Ans: The Types covered in the Anti-spasmodic Drugs Market report are Antimuscarinics, Smooth Muscle Relaxants

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Anti-spasmodic Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Antimuscarinics

1.2.3 Smooth Muscle Relaxants

1.3 Market by Application

1.3.1 Global Anti-spasmodic Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Offline Channel

1.3.3 Online Channel

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Anti-spasmodic Drugs Market Perspective (2019-2030)

2.2 Anti-spasmodic Drugs Growth Trends by Region

2.2.1 Global Anti-spasmodic Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Anti-spasmodic Drugs Historic Market Size by Region (2019-2024)

2.2.3 Anti-spasmodic Drugs Forecasted Market Size by Region (2025-2030)

2.3 Anti-spasmodic Drugs Market Dynamics

2.3.1 Anti-spasmodic Drugs Industry Trends

2.3.2 Anti-spasmodic Drugs Market Drivers

2.3.3 Anti-spasmodic Drugs Market Challenges

2.3.4 Anti-spasmodic Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Anti-spasmodic Drugs Players by Revenue

3.1.1 Global Top Anti-spasmodic Drugs Players by Revenue (2019-2024)

3.1.2 Global Anti-spasmodic Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Anti-spasmodic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Anti-spasmodic Drugs Revenue

3.4 Global Anti-spasmodic Drugs Market Concentration Ratio

3.4.1 Global Anti-spasmodic Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Anti-spasmodic Drugs Revenue in 2023

3.5 Anti-spasmodic Drugs Key Players Head office and Area Served

3.6 Key Players Anti-spasmodic Drugs Product Solution and Service

3.7 Date of Enter into Anti-spasmodic Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Anti-spasmodic Drugs Breakdown Data by Type

4.1 Global Anti-spasmodic Drugs Historic Market Size by Type (2019-2024)

4.2 Global Anti-spasmodic Drugs Forecasted Market Size by Type (2025-2030)

5 Anti-spasmodic Drugs Breakdown Data by Application

5.1 Global Anti-spasmodic Drugs Historic Market Size by Application (2019-2024)

5.2 Global Anti-spasmodic Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Anti-spasmodic Drugs Market Size (2019-2030)

6.2 North America Anti-spasmodic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Anti-spasmodic Drugs Market Size by Country (2019-2024)

6.4 North America Anti-spasmodic Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Anti-spasmodic Drugs Market Size (2019-2030)

7.2 Europe Anti-spasmodic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Anti-spasmodic Drugs Market Size by Country (2019-2024)

7.4 Europe Anti-spasmodic Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Anti-spasmodic Drugs Market Size (2019-2030)

8.2 Asia-Pacific Anti-spasmodic Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Anti-spasmodic Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Anti-spasmodic Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Anti-spasmodic Drugs Market Size (2019-2030)

9.2 Latin America Anti-spasmodic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Anti-spasmodic Drugs Market Size by Country (2019-2024)

9.4 Latin America Anti-spasmodic Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Anti-spasmodic Drugs Market Size (2019-2030)

10.2 Middle East & Africa Anti-spasmodic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Anti-spasmodic Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Anti-spasmodic Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Anti-spasmodic Drugs Introduction

11.1.4 Pfizer Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.1.5 Pfizer Recent Development

11.2 Allergan

11.2.1 Allergan Company Detail

11.2.2 Allergan Business Overview

11.2.3 Allergan Anti-spasmodic Drugs Introduction

11.2.4 Allergan Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.2.5 Allergan Recent Development

11.3 Ipsen

11.3.1 Ipsen Company Detail

11.3.2 Ipsen Business Overview

11.3.3 Ipsen Anti-spasmodic Drugs Introduction

11.3.4 Ipsen Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.3.5 Ipsen Recent Development

11.4 Teva Pharmaceuticals

11.4.1 Teva Pharmaceuticals Company Detail

11.4.2 Teva Pharmaceuticals Business Overview

11.4.3 Teva Pharmaceuticals Anti-spasmodic Drugs Introduction

11.4.4 Teva Pharmaceuticals Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.4.5 Teva Pharmaceuticals Recent Development

11.5 Novartis

11.5.1 Novartis Company Detail

11.5.2 Novartis Business Overview

11.5.3 Novartis Anti-spasmodic Drugs Introduction

11.5.4 Novartis Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.5.5 Novartis Recent Development

11.6 Johnson & Johnson

11.6.1 Johnson & Johnson Company Detail

11.6.2 Johnson & Johnson Business Overview

11.6.3 Johnson & Johnson Anti-spasmodic Drugs Introduction

11.6.4 Johnson & Johnson Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.6.5 Johnson & Johnson Recent Development

11.7 Takeda Pharmaceutical

11.7.1 Takeda Pharmaceutical Company Detail

11.7.2 Takeda Pharmaceutical Business Overview

11.7.3 Takeda Pharmaceutical Anti-spasmodic Drugs Introduction

11.7.4 Takeda Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.7.5 Takeda Pharmaceutical Recent Development

11.8 Sun Pharmaceutical Industries

11.8.1 Sun Pharmaceutical Industries Company Detail

11.8.2 Sun Pharmaceutical Industries Business Overview

11.8.3 Sun Pharmaceutical Industries Anti-spasmodic Drugs Introduction

11.8.4 Sun Pharmaceutical Industries Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.8.5 Sun Pharmaceutical Industries Recent Development

11.9 Merz Pharma

11.9.1 Merz Pharma Company Detail

11.9.2 Merz Pharma Business Overview

11.9.3 Merz Pharma Anti-spasmodic Drugs Introduction

11.9.4 Merz Pharma Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.9.5 Merz Pharma Recent Development

11.10 Mylan

11.10.1 Mylan Company Detail

11.10.2 Mylan Business Overview

11.10.3 Mylan Anti-spasmodic Drugs Introduction

11.10.4 Mylan Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.10.5 Mylan Recent Development

11.11 Fresenius Kabi

11.11.1 Fresenius Kabi Company Detail

11.11.2 Fresenius Kabi Business Overview

11.11.3 Fresenius Kabi Anti-spasmodic Drugs Introduction

11.11.4 Fresenius Kabi Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.11.5 Fresenius Kabi Recent Development

11.12 Endo International

11.12.1 Endo International Company Detail

11.12.2 Endo International Business Overview

11.12.3 Endo International Anti-spasmodic Drugs Introduction

11.12.4 Endo International Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.12.5 Endo International Recent Development

11.13 Daewoong Pharmaceutical

11.13.1 Daewoong Pharmaceutical Company Detail

11.13.2 Daewoong Pharmaceutical Business Overview

11.13.3 Daewoong Pharmaceutical Anti-spasmodic Drugs Introduction

11.13.4 Daewoong Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.13.5 Daewoong Pharmaceutical Recent Development

11.14 Acorda Therapeutics

11.14.1 Acorda Therapeutics Company Detail

11.14.2 Acorda Therapeutics Business Overview

11.14.3 Acorda Therapeutics Anti-spasmodic Drugs Introduction

11.14.4 Acorda Therapeutics Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.14.5 Acorda Therapeutics Recent Development

11.15 SteriMax

11.15.1 SteriMax Company Detail

11.15.2 SteriMax Business Overview

11.15.3 SteriMax Anti-spasmodic Drugs Introduction

11.15.4 SteriMax Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.15.5 SteriMax Recent Development

11.16 Emcure Pharmaceuticals

11.16.1 Emcure Pharmaceuticals Company Detail

11.16.2 Emcure Pharmaceuticals Business Overview

11.16.3 Emcure Pharmaceuticals Anti-spasmodic Drugs Introduction

11.16.4 Emcure Pharmaceuticals Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.16.5 Emcure Pharmaceuticals Recent Development

11.17 Sawai Pharmaceutical

11.17.1 Sawai Pharmaceutical Company Detail

11.17.2 Sawai Pharmaceutical Business Overview

11.17.3 Sawai Pharmaceutical Anti-spasmodic Drugs Introduction

11.17.4 Sawai Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.17.5 Sawai Pharmaceutical Recent Development

11.18 Orient Pharma

11.18.1 Orient Pharma Company Detail

11.18.2 Orient Pharma Business Overview

11.18.3 Orient Pharma Anti-spasmodic Drugs Introduction

11.18.4 Orient Pharma Revenue in Anti-spasmodic Drugs Business (2019-2024)

11.18.5 Orient Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Takeda Pharmaceutical

Sun Pharmaceutical Industries

Daewoong Pharmaceutical

Acorda Therapeutics

Sterimax

Emcure Pharmaceuticals

Sawai Pharmaceutical

Orient Pharma

List of Tables

Table 1. Global Anti-spasmodic Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Antimuscarinics

Table 3. Key Players of Smooth Muscle Relaxants

Table 4. Global Anti-spasmodic Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Anti-spasmodic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Anti-spasmodic Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Anti-spasmodic Drugs Market Share by Region (2019-2024)

Table 8. Global Anti-spasmodic Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Anti-spasmodic Drugs Market Share by Region (2025-2030)

Table 10. Anti-spasmodic Drugs Market Trends

Table 11. Anti-spasmodic Drugs Market Drivers

Table 12. Anti-spasmodic Drugs Market Challenges

Table 13. Anti-spasmodic Drugs Market Restraints

Table 14. Global Anti-spasmodic Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Anti-spasmodic Drugs Market Share by Players (2019-2024)

Table 16. Global Top Anti-spasmodic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-spasmodic Drugs as of 2023)

Table 17. Ranking of Global Top Anti-spasmodic Drugs Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Anti-spasmodic Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Anti-spasmodic Drugs Product Solution and Service

Table 21. Date of Enter into Anti-spasmodic Drugs Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Anti-spasmodic Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Anti-spasmodic Drugs Revenue Market Share by Type (2019-2024)

Table 25. Global Anti-spasmodic Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Anti-spasmodic Drugs Revenue Market Share by Type (2025-2030)

Table 27. Global Anti-spasmodic Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Anti-spasmodic Drugs Revenue Market Share by Application (2019-2024)

Table 29. Global Anti-spasmodic Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Anti-spasmodic Drugs Revenue Market Share by Application (2025-2030)

Table 31. North America Anti-spasmodic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Anti-spasmodic Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Anti-spasmodic Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Anti-spasmodic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Anti-spasmodic Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Anti-spasmodic Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Anti-spasmodic Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Anti-spasmodic Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Anti-spasmodic Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Anti-spasmodic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Anti-spasmodic Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Anti-spasmodic Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Anti-spasmodic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Anti-spasmodic Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Anti-spasmodic Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 46. Pfizer Company Detail

Table 47. Pfizer Business Overview

Table 48. Pfizer Anti-spasmodic Drugs Product

Table 49. Pfizer Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 50. Pfizer Recent Development

Table 51. Allergan Company Detail

Table 52. Allergan Business Overview

Table 53. Allergan Anti-spasmodic Drugs Product

Table 54. Allergan Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 55. Allergan Recent Development

Table 56. Ipsen Company Detail

Table 57. Ipsen Business Overview

Table 58. Ipsen Anti-spasmodic Drugs Product

Table 59. Ipsen Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 60. Ipsen Recent Development

Table 61. Teva Pharmaceuticals Company Detail

Table 62. Teva Pharmaceuticals Business Overview

Table 63. Teva Pharmaceuticals Anti-spasmodic Drugs Product

Table 64. Teva Pharmaceuticals Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 65. Teva Pharmaceuticals Recent Development

Table 66. Novartis Company Detail

Table 67. Novartis Business Overview

Table 68. Novartis Anti-spasmodic Drugs Product

Table 69. Novartis Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 70. Novartis Recent Development

Table 71. Johnson & Johnson Company Detail

Table 72. Johnson & Johnson Business Overview

Table 73. Johnson & Johnson Anti-spasmodic Drugs Product

Table 74. Johnson & Johnson Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 75. Johnson & Johnson Recent Development

Table 76. Takeda Pharmaceutical Company Detail

Table 77. Takeda Pharmaceutical Business Overview

Table 78. Takeda Pharmaceutical Anti-spasmodic Drugs Product

Table 79. Takeda Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 80. Takeda Pharmaceutical Recent Development

Table 81. Sun Pharmaceutical Industries Company Detail

Table 82. Sun Pharmaceutical Industries Business Overview

Table 83. Sun Pharmaceutical Industries Anti-spasmodic Drugs Product

Table 84. Sun Pharmaceutical Industries Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 85. Sun Pharmaceutical Industries Recent Development

Table 86. Merz Pharma Company Detail

Table 87. Merz Pharma Business Overview

Table 88. Merz Pharma Anti-spasmodic Drugs Product

Table 89. Merz Pharma Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 90. Merz Pharma Recent Development

Table 91. Mylan Company Detail

Table 92. Mylan Business Overview

Table 93. Mylan Anti-spasmodic Drugs Product

Table 94. Mylan Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 95. Mylan Recent Development

Table 96. Fresenius Kabi Company Detail

Table 97. Fresenius Kabi Business Overview

Table 98. Fresenius Kabi Anti-spasmodic Drugs Product

Table 99. Fresenius Kabi Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 100. Fresenius Kabi Recent Development

Table 101. Endo International Company Detail

Table 102. Endo International Business Overview

Table 103. Endo International Anti-spasmodic Drugs Product

Table 104. Endo International Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 105. Endo International Recent Development

Table 106. Daewoong Pharmaceutical Company Detail

Table 107. Daewoong Pharmaceutical Business Overview

Table 108. Daewoong Pharmaceutical Anti-spasmodic Drugs Product

Table 109. Daewoong Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 110. Daewoong Pharmaceutical Recent Development

Table 111. Acorda Therapeutics Company Detail

Table 112. Acorda Therapeutics Business Overview

Table 113. Acorda Therapeutics Anti-spasmodic Drugs Product

Table 114. Acorda Therapeutics Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 115. Acorda Therapeutics Recent Development

Table 116. SteriMax Company Detail

Table 117. SteriMax Business Overview

Table 118. SteriMax Anti-spasmodic Drugs Product

Table 119. SteriMax Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 120. SteriMax Recent Development

Table 121. Emcure Pharmaceuticals Company Detail

Table 122. Emcure Pharmaceuticals Business Overview

Table 123. Emcure Pharmaceuticals Anti-spasmodic Drugs Product

Table 124. Emcure Pharmaceuticals Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 125. Emcure Pharmaceuticals Recent Development

Table 126. Sawai Pharmaceutical Company Detail

Table 127. Sawai Pharmaceutical Business Overview

Table 128. Sawai Pharmaceutical Anti-spasmodic Drugs Product

Table 129. Sawai Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 130. Sawai Pharmaceutical Recent Development

Table 131. Orient Pharma Company Detail

Table 132. Orient Pharma Business Overview

Table 133. Orient Pharma Anti-spasmodic Drugs Product

Table 134. Orient Pharma Revenue in Anti-spasmodic Drugs Business (2019-2024) & (US$ Million)

Table 135. Orient Pharma Recent Development

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Anti-spasmodic Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Anti-spasmodic Drugs Market Share by Type: 2023 VS 2030

Figure 3. Antimuscarinics Features

Figure 4. Smooth Muscle Relaxants Features

Figure 5. Global Anti-spasmodic Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Anti-spasmodic Drugs Market Share by Application: 2023 VS 2030

Figure 7. Offline Channel Case Studies

Figure 8. Online Channel Case Studies

Figure 9. Anti-spasmodic Drugs Report Years Considered

Figure 10. Global Anti-spasmodic Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 11. Global Anti-spasmodic Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Anti-spasmodic Drugs Market Share by Region: 2023 VS 2030

Figure 13. Global Anti-spasmodic Drugs Market Share by Players in 2023

Figure 14. Global Top Anti-spasmodic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-spasmodic Drugs as of 2023)

Figure 15. The Top 10 and 5 Players Market Share by Anti-spasmodic Drugs Revenue in 2023

Figure 16. North America Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 17. North America Anti-spasmodic Drugs Market Share by Country (2019-2030)

Figure 18. United States Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. Canada Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Europe Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Anti-spasmodic Drugs Market Share by Country (2019-2030)

Figure 22. Germany Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. France Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. U.K. Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Italy Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Russia Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Nordic Countries Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Asia-Pacific Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Anti-spasmodic Drugs Market Share by Region (2019-2030)

Figure 30. China Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Japan Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. South Korea Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Southeast Asia Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. India Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Australia Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Latin America Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Anti-spasmodic Drugs Market Share by Country (2019-2030)

Figure 38. Mexico Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Brazil Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Middle East & Africa Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Anti-spasmodic Drugs Market Share by Country (2019-2030)

Figure 42. Turkey Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Saudi Arabia Anti-spasmodic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Pfizer Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 45. Allergan Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 46. Ipsen Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 47. Teva Pharmaceuticals Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 48. Novartis Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 49. Johnson & Johnson Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 50. Takeda Pharmaceutical Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 51. Sun Pharmaceutical Industries Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 52. Merz Pharma Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 53. Mylan Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 54. Fresenius Kabi Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 55. Endo International Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 56. Daewoong Pharmaceutical Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 57. Acorda Therapeutics Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 58. SteriMax Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 59. Emcure Pharmaceuticals Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 60. Sawai Pharmaceutical Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 61. Orient Pharma Revenue Growth Rate in Anti-spasmodic Drugs Business (2019-2024)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-24G3922

Fri Oct 11 00:00:00 UTC 2024

Add to Cart

Muscle Relaxants Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-28K7363

Fri Oct 11 00:00:00 UTC 2024

Add to Cart

Drugs for Short Bowel Syndrome - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-19D6153

Tue Oct 08 00:00:00 UTC 2024

Add to Cart

Ischemic Cerebral Stroke Prevention Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-35V13407

Tue Oct 08 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Anti-spasmodic Drugs Market Research Report 2024

Published Date: January 2024

Report Code: QYRE-Auto-9L6046

Global Anti-spasmodic Drugs Market Research Report 2024

FEATURED COMPANIES

Anti-spasmodic Drugs Market Size

Anti-spasmodic Drugs Market

Report Scope

Scope of Anti-spasmodic Drugs Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Anti-spasmodic Drugs Market report?

What are the Application segmentation covered in the Anti-spasmodic Drugs Market report?

What are the Type segmentation covered in the Anti-spasmodic Drugs Market report?

FEATURED COMPANIES

RELATED REPORTS